Continuous arteriovenous hemofiltration in premature infants

Area of Science:

• Pediatric Nephrology
• Neonatal Intensive Care
• Renal Replacement Therapy

Background:

• Critically ill premature infants often develop acute renal failure (ARF) and hypervolemia.
• Managing fluid and metabolic disturbances in this population presents significant clinical challenges.

Purpose of the Study:

• To evaluate the efficacy and safety of continuous arteriovenous hemofiltration (CAVH) in critically ill premature infants with ARF and hypervolemia.
• To assess CAVH's impact on fluid balance, renal function markers, and overall outcomes.

Main Methods:

• CAVH was implemented in five critically ill premature infants diagnosed with ARF and hypervolemia.
• Prostacyclin was administered to mitigate hemofilter clotting during treatment.
• Treatment parameters including duration, blood flow rates, filtration fractions, and ultrafiltration rates were monitored.

Main Results:

• CAVH successfully corrected fluid overload in all treated infants.
• Mean serum creatinine and urea levels showed minimal changes post-CAVH, indicating stabilization rather than significant clearance.
• Hemofilter clotting occurred approximately every 14 hours, and urinary output was restored in three infants.
• Three infants expired, but deaths were not attributed to ARF or the CAVH procedure.

Conclusions:

• CAVH is a safe and feasible method for managing fluid and metabolic imbalances in critically ill premature infants with ARF.
• The technique demonstrates potential for stabilizing these vulnerable patients, although further research is warranted.
• While CAVH did not significantly alter creatinine or urea levels, it effectively addressed hypervolemia and supported renal function restoration in some cases.